Drug Discovery
By
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in Drug Development?
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a Turning Point for Generative-AI-Designed Small Molecules?
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with Merck to deploy…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
How Is Senhwa Biosciences Using AI and Strategic Collaborations to Shape the Next Generation of Immuno-Oncology?
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device Innovation?
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
